Teva Pharmaceutical Industries Limited
TEVJF
$16.11
$2.3116.74%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -168.48% | -192.68% | 58.96% | 80.72% | 71.99% |
| Total Depreciation and Amortization | -8.03% | -8.15% | -11.48% | -12.27% | -13.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 123.27% | 167.06% | -28.49% | -60.84% | -34.17% |
| Change in Net Operating Assets | -190.00% | -504.17% | 737.50% | -245.39% | -149.33% |
| Cash from Operations | -8.86% | -8.85% | 60.41% | -31.09% | -7.03% |
| Capital Expenditure | 1.96% | 5.32% | 11.11% | 6.32% | 3.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | -- | -- | -- | -- |
| Divestitures | -9.09% | -36.76% | -57.14% | -86.75% | 46.67% |
| Other Investing Activities | -7.26% | -11.50% | 4.80% | 5.09% | 19.91% |
| Cash from Investing | -8.81% | -18.18% | 6.71% | 1.13% | 37.93% |
| Total Debt Issued | -- | -- | -100.00% | -71.44% | -71.44% |
| Total Debt Repaid | -77.00% | 66.18% | 71.23% | 37.14% | 62.40% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4.75% | 29.25% | -70.50% | -128.47% | -188.71% |
| Cash from Financing | -149.19% | 6.38% | 17.33% | -18.73% | 38.10% |
| Foreign Exchange rate Adjustments | 82.88% | -480.00% | -68.75% | -3,833.33% | -197.96% |
| Miscellaneous Cash Flow Adjustments | 100.00% | -- | -- | -- | -- |
| Net Change in Cash | -258.77% | -81.42% | 13,462.50% | -171.16% | 1,201.35% |